Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss
A study presented at ENDO 2026 indicates that semaglutide (Ozempic) is associated with a 15% lower risk of bone fractures compared to other weight-loss medications. Researchers suggest this may be a protective benefit for patients with type 2 diabetes.
Why it matters
This finding could influence clinical guidelines for prescribing weight-loss drugs to patients concerned about bone health.
A new study suggests that semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected benefit for people with type 2 diabetes. Researchers found that patients taking the medication experienced fewer bone fractures and greater weight loss than those using several other anti-obesity treatments.
The article reports on medical research findings without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in